The Medicines and Healthcare products Regulatory Agency (MHRA) has today (15 November 2023) extended the licence of the cystic fibrosis medicines Kaftrio (ivacaftor, tezacaftor and elexacaftor) and Kalydeco (ivacaftor) for children aged two to five years old.
Harris Poll notes increase in pharma reputation among Americans who know about GLP-1 drugs
GLP-1 medications are helping to boost the pharma industry’s reputation in the US. That’s according to a Harris Poll run recently to gauge general public